NCT05156320已完成3 期
Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients With Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 188
- 试验地点
- 95
- 主要终点
- Main Efficacy Population: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score.
研究概览
简要总结
This Phase 3 trial (Study SRK-015-003) was conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and were receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Active treatment, randomized, double-blind, placebo-controlled.
入排标准
- 年龄范围
- 2 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 2 through 21 years old at Screening.
- •Documented diagnosis of 5q SMA.
- •Diagnosed with later-onset SMA (i.e., Type 2 and Type 3 SMA) before receiving an approved SMN upregulator therapy (i.e., either nusinersen or risdiplam).
- •Must be Nonambulatory at Screening. Nonambulatory patients must be able to sit independently (sits up straight with head erect for at least 10 seconds; does not use arms or hands to balance body or support position) per World Health Organization (WHO) motor milestones definition at Screening.
- •Receiving one background therapy for SMA (i.e., either nusinersen or risdiplam) for the time period specified below and anticipated to remain on that same treatment throughout the trial:
- •If receiving the SMN upregulator therapy nusinersen, must have completed at least 10 months of dosing (i.e., completed the loading regimen and at least 2 maintenance doses) before Screening;
- •If receiving the SMN upregulator therapy risdiplam, must have completed at least 6 months of dosing before Screening.
- •Motor Function Score (HFMSE) ≥10 and ≤45 at Screening.
- •Have no physical limitations that would prevent the patient from undergoing motor function outcome measures throughout the duration of the study.
- •Able to receive study drug infusions and provide blood samples through the use of a peripheral intravenous (IV) or a long-term IV access device that the patient has placed for reasons independent from the study throughout the duration of the study.
- •Able to adhere to the requirements of the protocol, including travel to the study center and completing all study procedures and study visits.
- •For patients who are expected to have reached reproductive maturity by the end of the study, adhere to study specific contraception requirements.
排除标准
- •Received ZOLGENSMA® (onasemnogene abeparvovec-xioi) at any time and previous treatment with apitegromab.
- •Use of invasive ventilation and tracheostomy.
- •Use of chronic daytime non-invasive ventilatory support for >16 hours daily in the 2 weeks prior to dosing, or anticipated to regularly receive such daytime ventilator support chronically over the duration of the study.
- •Any acute or co-morbid condition interfering with the well-being of the patient within 7 days of screening, including active systemic infection, the need for acute treatment or inpatient observation due to any reason.
- •Severe scoliosis and/or contractures at screening. Based on clinical judgement, any scoliosis or contractures present must be stable over the past 6 months, anticipated to be stable for the duration of the study and not prevent the patient from being evaluated on any functional outcome measures throughout the duration of the study.
- •Pregnant or breastfeeding.
- •Major orthopedic or other interventional procedure, including spine or hip surgery, considered to have the potential to substantially limit the ability of the patient to be evaluated on any functional outcome measures, within 6 months prior to Screening, or anticipated for the duration of the study.
- •Prior history of a hypersensitivity reaction to a monoclonal antibody (mAb) or recombinant protein bearing an Fc domain (such as a soluble receptor-Fc fusion protein), apitegromab, or excipients of apitegromab.
- •Treatment with investigational drugs within 3 months prior to Screening.
- •Use of therapies with potentially significant muscle effects (such as androgens, insulin-like growth factor, growth hormone, systemic beta-agonist, botulinum toxin, or muscle relaxants or muscle-enhancing supplements) or potentially significant neuromuscular effects (such as acetylcholinesterase inhibitors) within 60 days prior to screening.
- •Nutritional status not stable over the past 6 months and not anticipated to be stable throughout the duration of the study.
- •Patient has any other condition, which in the opinion of the Investigator may compromise safety or compliance, would preclude the patient from successful completion of the study, or interfere with the interpretation of the results.
研究组 & 干预措施
Main Efficacy Population (Apitegromab 10 mg/kg)
Experimental
Aged 2-12 years at Screening. Participants were randomized to receive apitegromab 10 mg/kg for up to 52 weeks.
干预措施: Apitegromab (Drug)
Main Efficacy Population (Apitegromab 20 mg/kg)
Experimental
Aged 2-12 years at Screening. Participants were randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
干预措施: Apitegromab (Drug)
Main Efficacy Population (Placebo)
Placebo Comparator
Aged 2-12 years at Screening. Participants were randomized to receive placebo for up to 52 weeks.
干预措施: Placebo (Drug)
Exploratory Subpopulation (Apitegromab)
Experimental
Aged 13-21 years at Screening. Participants were randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
干预措施: Apitegromab (Drug)
Exploratory Subpopulation (Placebo)
Placebo Comparator
Aged 13-21 years at Screening. Participants were randomized to receive placebo for up to 52 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Main Efficacy Population: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score.
时间窗: Baseline up to 12 months.
The HFMSE assesses the physical abilities of patients with Type 2 and Type 3 SMA. It comprises of 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function.
次要结局
- Main Efficacy Population: Change from Baseline in Revised Upper Limb Module (RULM) total score.(Baseline up to 12 months.)
- Main Efficacy Population: Proportion of patients with ≥3-point change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score.(Baseline up to 12 months.)
- Main Efficacy Population: Change from Baseline in number of WHO motor development milestones attained at 12 months.(Baseline up to 12 months.)
- Main Efficacy Population and Exploratory Subpopulation combined: Incidence of Treatment Emergent Adverse Events (TEAEs) and Severe Adverse Events (SAEs) by severity.(Baseline up to 12 months.)
- Main Efficacy Population and Exploratory Subpopulation combined: Apitegromab concentrations in serum from blood samples.(Baseline up to 12 months.)
- Main Efficacy Population and Exploratory Subpopulation combined: Circulating latent myostatin concentrations in blood samples.(Baseline up to 12 months.)
- Main Efficacy Population and Exploratory Subpopulation combined: Presence or absence of Antidrug Antibody (ADA) against apitegromab in serum from blood samples.(Baseline up to 12 months.)
研究者
研究点 (95)
Loading locations...
相似试验
撤回
3 期
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic DermatitisAtopic DermatitisNCT05614817Suzhou Connect Biopharmaceuticals, Ltd.
进行中（未招募）
3 期
A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia SyndromeFamilial Chylomicronemia SyndromeNCT05902598Visirna Therapeutics HK Limited37
进行中（未招募）
3 期
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaqueCoronary Artery DiseaseLipidemiaPlaque, AtheroscleroticNCT06305559NewAmsterdam Pharma300
撤回
3 期
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT06735079MGGM LLC146
Unknown
不适用
Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic StrokeAcute Ischemic StrokeNCT03519737Cerevast Medical, Inc.596
相关资讯
Key Clinical Trial Outcomes of 2024: HIV PrEP, SMA, Obesity, and Alzheimer's Disease• Gilead's lenacapavir demonstrated near-perfect efficacy as a twice-yearly injectable for HIV PrEP in Phase III trials, offering a promising alternative to daily oral treatments.
• Scholar Rock's apitegromab met its primary endpoint in a Phase III SMA trial, showing statistically significant and clinically meaningful improvements in motor function.
• Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head Phase IIIb trial for weight loss, demonstrating a 47% greater relative weight loss.
• Eisai's Leqembi showed positive data in a Phase III open-label extension study for Alzheimer's disease, reducing cognitive decline compared to expected decline.last yearScholar Rock's Apitegromab Shows Clinically Meaningful Improvement in Phase 3 SMA Trial- Scholar Rock's apitegromab met its primary endpoint in the Phase 3 SAPPHIRE trial, demonstrating statistically significant improvement in motor function for SMA patients.
- The trial showed a 1.8-point improvement in motor function compared to placebo, as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE).
- Scholar Rock plans to submit regulatory applications to the FDA and EMA in Q1 2025, potentially launching the drug in the US by Q4 2025.
- Apitegromab was well-tolerated, with a safety profile consistent with previous studies, and 98% of patients enrolled in an open-label extension study.last year